What is the official ID of this bill?
The official print number for this legislation is HR 6963.
Pediatric Cancer Drug Supply Act: Ensuring Access to Critical Therapies.
This act aims to ensure the continuous availability of essential pediatric cancer drugs by establishing strategic reserves. This will provide peace of mind for parents and patients regarding treatment continuity, even during market shortages. The program is designed to protect the youngest patients from treatment interruptions that could have serious consequences.
Key points
Creating drug reserves: The Secretary of Health and Human Services will enter into agreements with manufacturers to maintain at least a 6-month reserve supply of key pediatric cancer drugs.
Essential drug list: A list of chemotherapeutic drugs deemed essential for treating pediatric cancer will be developed and regularly updated.
Preventing shortages: In case of a drug shortage, the Secretary can order manufacturers to distribute drugs from reserves to ensure treatment continuity.
Supporting domestic manufacturing: The program aims to encourage increased domestic drug manufacturing capacity and promote market competition.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.